UnitedHealth Group Incorporated Revenue, History, and Strategy

UnitedHealth Group Incorporated: Key Facts

• UnitedHealth Group Incorporated was founded in 1977.
• Founded by Richard T. Burke.
• Headquarters: Minnetonka, Minnesota.
• Country: United States.
• CEO: Stephen Hemsley.
• Approximately 440K employees worldwide.
• Market capitalization: $290.0B.
• Annual revenue: $400.3B (FY2024).
• Net income: $16.4B.
• Publicly traded: UNH.
• Industry: Managed Healthcare & Health Services.
• Listed on a public stock exchange.
• UnitedHealth Group reported total revenues of $400.3 billion for fiscal year 2024, placing it second on the Fortune 500 behind only Walmart — its revenue exceeds the GDP of Denmark, Finland, or Portugal.
• The Change Healthcare ransomware attack in February 2024 cost UnitedHealth Group over $3.1 billion in direct remediation costs, provider advance payments, and disruption expenses, making it the most financially damaging cyberattack in US healthcare history.
• Optum employs more than 60,000 physicians, nurse practitioners, and physician assistants across more than 2,000 care delivery sites, making it among the largest direct employers of medical professionals in the United States.
• OptumRx manages pharmacy benefits for over 65 million people, ranking it as one of the top three pharmacy benefit managers nationally alongside Express Scripts (Evernorth/Cigna) and CVS Caremark.
• UnitedHealthcare is the largest Medicare Advantage insurer in the United States with over 8.7 million enrollees, representing more than 20 percent of total national Medicare Advantage enrollment.
• The company has grown its annual revenue from approximately $87 billion in 2008 to $400 billion in 2024, a compounding growth rate driven almost entirely by organic expansion and domestic acquisitions rather than international revenue.
• UnitedHealth Group's $400.3 billion in FY2024 revenue makes it the second-largest US corporation by revenue — ahead of Apple, Amazon, and every bank in the world — generated almost entirely within the American healthcare system.
• The February 2024 Change Healthcare ransomware attack, which cost UnitedHealth Group over $3.1 billion in direct expenses, disrupted approximately one-third of all US medical claims processing for weeks and was the most financially damaging cyberattack in healthcare history.
• Optum, the company's health services division, employs more than 60,000 physicians and advanced practice clinicians — making it one of the largest single employers of physicians in the United States, comparable in physician headcount to the largest academic health systems.
• UnitedHealth Group has grown from under $100 billion in annual revenue in 2010 to over $400 billion in 2024 — a more than 300% revenue increase in fourteen years — primarily by assembling a vertically integrated stack that captures pharmacy, care delivery, and data economics alongside insurance premiums.

UnitedHealth Group Incorporated: UnitedHealth Group Incorporated: UnitedHealth Group Incorporated Company Timeline

What Is the History of UnitedHealth Group Incorporated?

The story of UnitedHealth Group begins not with a business plan but with an idea — specifically, with Paul Ellwood's idea that American healthcare could be reorganized around preventive, coordinated, prepaid medical care delivered through organizations that Ellwood himself named health maintenance organizations. Ellwood, a Minneapolis-based pediatric neurologist turned healthcare policy advocate, had been promoting the HMO concept since the late 1960s as an alternative to the fee-for-service insurance model that he believed incentivized procedure volume over patient health outcomes. His advocacy reached Washington in 1971, when he briefed members of the Nixon administration on the concept at a meeting that Ellwood later described as a turning point for managed care policy; two years later, in 1973, Congress passed the Health Maintenance Organization Act, which provided federal seed funding to establish HMOs, required employers with more than 25 employees to offer an HMO option if one was locally available, and established a federal regulatory framework for the new organizational form.

The HMO Act created a market but not the organizations to fill it. Building entities capable of contracting with physicians, managing utilization, collecting premiums, and operating sustainably within the new regulatory framework required a different set of capabilities than policy advocacy — administrative infrastructure, actuarial expertise, and the organizational discipline to manage medical risk at scale. Into that gap stepped a generation of healthcare administrators, insurance executives, and entrepreneurially minded physicians who saw in the HMO legislation an opportunity to construct managed care companies capable of competing with traditional indemnity insurance.

Richard T. Burke was among the most consequential of these builders. Burke had grown up in the Upper Midwest and completed his education at the University of Notre Dame before pursuing a career in insurance and healthcare administration. By the early 1970s, he had become involved with Charter Med Incorporated, a Minneapolis-based organization founded specifically to manage health maintenance organizations for employers and labor unions in Minnesota and surrounding states. Charter Med operated in the ideological orbit of Paul Ellwood's Group Health Foundation and the broader Minneapolis managed care ecosystem, which was by the mid-1970s among the most developed in the nation. The intellectual environment of Minneapolis-area managed care — combining Ellwood's population health philosophy with the practical demands of union-negotiated employee benefits and the commercial insurance expertise of a mature Upper Midwest insurance industry — gave Burke an unusually complete education in both the theory and the operational reality of prepaid healthcare.

In 1977, Charter Med was reorganized and United HealthCare Corporation was incorporated in Minnetonka, Minnesota, a suburb approximately twenty miles west of Minneapolis that would remain the company's headquarters for the next five decades. The new company's founding mandate was operationally focused: manage the administrative and financial functions of health maintenance organizations being operated by hospitals, employers, and physician groups that lacked the dedicated management infrastructure to run them efficiently. United HealthCare was, in its earliest form, a contract management company — an organization that provided operational expertise to HMO owners who retained the capital at risk — rather than an insurance company bearing its own premium risk.

This initial model proved strategically shrewd. By managing others' HMOs rather than immediately underwriting its own risk, United HealthCare accumulated operational knowledge, management systems, and actuarial experience without the capital requirements of a traditional insurance startup. Each managed HMO provided a laboratory for improving medical management protocols, claims processing efficiency, provider contracting techniques, and the population health analytics that distinguished the most financially successful managed care plans from the many that failed on medical cost management in the early years of the industry.

By the early 1980s, United HealthCare had leveraged its management expertise into direct ownership of HMO plans across multiple states, with Minnesota remaining its operational base. The company's growth track record attracted institutional investor attention, and in 1984, United HealthCare Corporation completed its initial public offering on the New York Stock Exchange. The IPO was transformative: it converted a closely held HMO management company into a publicly capitalized corporation with access to equity markets for acquisitions and expansion. Within seven years of its founding, Burke had built the financial architecture necessary to compete for acquisition targets and geographic expansion at a national level — an achievement that most of the hundreds of other HMO management companies formed in the wake of the 1973 HMO Act never approached.

Burke stepped down as CEO in 1988 after eleven years of leadership, passing an organization that had grown from a regional contract manager to a multi-state managed care operator with millions of enrolled members and hundreds of millions in annual revenue. His successors through the late 1980s and into the 1990s confronted the turbulent middle years of the managed care era: the Clinton healthcare reform debate of 1993-1994, which raised and then dashed HMO operators' hopes for a regulated competition framework; the national managed care backlash of the mid-1990s, driven by consumer and physician anger about coverage restrictions, gatekeeper models, and cost containment practices that patients experienced as care withholding; and the operational complexity of integrating the wave of regional HMO acquisitions that United HealthCare pursued to build national scale.

The defining acquisition of the decade came in 1995, when United HealthCare agreed to purchase MetraHealth for approximately $1.65 billion. MetraHealth had been formed as a joint venture between MetLife and Travelers Group, combining the health insurance operations of two major life insurers that had determined managed care scale was beyond their individual reach. The MetraHealth transaction roughly doubled United HealthCare's membership and transformed it from a Midwest-centered managed care operator into a genuinely national insurer with commercial accounts across all major US markets. The deal positioned United HealthCare — renamed UnitedHealth Group in 1998 — as one of the handful of managed care organizations with the national scale to compete for the largest US employers' healthcare contracts.

Under CEO William McGuire, who led the company from 1991 to 2006, UnitedHealth Group began articulating a strategic vision that extended beyond traditional insurance risk-bearing toward health information, data analytics, and services. McGuire recognized earlier than most in the industry that health data — the longitudinal record of diagnoses, treatments, costs, and outcomes — was a strategic asset as valuable as the insurance premium float, and he began assembling the technology and analytics businesses that would eventually become Optum. His tenure ended in 2006 amid a stock options backdating controversy, but the dual-platform architecture he established became the blueprint that Stephen Hemsley executed with even greater ambition during his decade-long tenure as CEO from 2006 to 2017 — years during which Optum grew from an internal data operation into a $100 billion-plus health services enterprise that now employs more people and processes more revenue than many Fortune 500 companies operating entirely independently.

UnitedHealth Group Incorporated is the largest managed healthcare and health services enterprise in the United States, bringing together two distinct but deeply integrated business platforms under a single corporate structure. The UnitedHealthcare platform provides medical benefits coverage to approximately 50 million Americans across employer-sponsored commercial plans, Medicare Advantage and Medicare Supplement programs for seniors, Medicaid managed care contracts for low-income populations across more than 30 states, and insurance products in select international markets. The Optum platform delivers health services through three operating businesses: OptumRx, a top-three pharmacy benefit manager serving over 65 million members; Optum Health, a care delivery organization employing more than 60,000 clinicians across primary care, multi-specialty, home health, and ambulatory surgical settings; and Optum Insight, a health information technology and analytics company serving hospitals, health plans, government agencies, and life sciences clients with revenue cycle management, data analytics, and clinical decision support tools.

The company is headquartered in Minnetonka, Minnesota, where it has been based since its founding in 1977, and its approximately 440,000 employees operate in facilities spanning every state in the nation and multiple international markets. UnitedHealth Group has been a component of the S&P 500 for decades and trades on the New York Stock Exchange under the ticker symbol UNH. For fiscal year 2024, the company reported total revenues of $400.3 billion, making it the second-largest corporation in the United States by revenue. The dual-platform model — UnitedHealthcare providing insurance scale and member relationships, Optum providing higher-margin services to both internal and external clients — has driven revenue growth from under $100 billion in 2010 to over $400 billion in 2024, a compounding trajectory with few parallels in American corporate history. The company currently operates under the leadership of Stephen Hemsley, who returned as CEO in May 2025 following Andrew Witty's resignation, and faces a regulatory and reputational environment considerably more challenging than at any prior point in the enterprise's history.

Early Challenges

UnitedHealth Group's origins are far more modest than its current $400 billion revenue suggests. In 1974, a group of physicians in Minneapolis formed a small health maintenance organization (HMO) called Charter Med Incorporated, offering prepaid healthcare to local employers. The concept was simple but radical for the era: instead of traditional fee-for-service medicine where doctors were paid for each procedure (creating incentives to over-treat), the HMO would receive a fixed monthly payment per member and manage their total healthcare — creating incentives to keep people healthy and avoid unnecessary procedures.

Richard T. Burke, a young healthcare entrepreneur, saw opportunity in the nascent HMO movement. In 1977, he organized United HealthCare Corporation to acquire and manage struggling HMOs across the Midwest. The timing was deliberate: the federal HMO Act of 1973 had required large employers to offer HMO options alongside traditional insurance, creating a wave of new HMOs — many of which were poorly managed and losing money. Burke's strategy was to acquire these distressed HMOs cheaply, professionalize their management, and achieve scale economies.

The early years were a constant struggle for survival. HMOs in the late 1970s were deeply unpopular with both doctors (who resented managed care's restrictions on their autonomy) and patients (who disliked being told which doctors they could see). United HealthCare had to convince employers that HMOs could reduce healthcare costs without sacrificing quality — a hard sell when the HMO concept was associated with rationing and bureaucracy.

Funding was precarious. Burke raised capital through a series of small private placements, barely keeping the company solvent as it acquired one struggling HMO after another. Each acquisition brought new members but also new losses that had to be turned around through better management. The company operated on razor-thin margins — health insurance is inherently a low-margin business where a few expensive claims can wipe out months of premium income.

The 1980s brought rapid growth but also near-catastrophic growing pains. United HealthCare went public in 1984, raising capital to fund more acquisitions. By the mid-1980s, the company had assembled a patchwork of HMOs across multiple states, but integrating them into a coherent operation proved enormously difficult. Each acquired HMO had different provider networks, different benefit designs, different IT systems, and different cultures. The company was growing revenue but struggling to achieve the operational efficiencies that would make the model profitable at scale.

The managed care backlash of the early 1990s nearly destroyed the entire HMO industry — and United HealthCare with it. As HMOs grew and began aggressively restricting care to control costs, a public revolt erupted. Horror stories of denied claims, refused treatments, and patients dying because their HMO wouldn't authorize procedures dominated the news. State legislatures passed 'patient bill of rights' laws restricting HMO practices. Lawsuits multiplied. The term 'managed care' became an epithet.

United HealthCare was caught in this backlash. The company had grown to become one of the largest HMOs in America, but its aggressive cost management practices generated the same public anger directed at the entire industry. Membership growth stalled as employers and employees pushed back against HMO restrictions. The company's stock price stagnated through the mid-1990s as investors questioned whether the managed care model was politically sustainable.

The crisis deepened in 1998 when United HealthCare reported a $900 million loss — a staggering sum that reflected both medical cost miscalculations and the costs of integrating too many acquisitions too quickly. The company had expanded into markets it didn't understand, underpriced premiums to win contracts, and then faced medical costs far exceeding what it had collected in premiums. CEO William McGuire (who had replaced Burke in 1991) faced calls for his resignation.

McGuire's response was transformative: rather than retreating, he restructured the company around a new vision. Instead of being just a health insurer that managed costs through restrictions, United HealthCare would become a health services company that added value through technology, data analytics, and care management. This vision led to the creation of Optum in 2011 (though its components were assembled throughout the 2000s) — the health services platform that would eventually generate more revenue than the insurance business itself.

The early 2000s brought another crisis: the stock options backdating scandal. In 2006, an investigation revealed that CEO William McGuire had received over $1.6 billion in stock options that appeared to have been backdated to maximize their value. McGuire was forced to resign, paid $468 million in restitution, and the scandal tarnished UnitedHealth's reputation at a time when public trust in health insurers was already low. The company brought in Stephen Hemsley (McGuire's deputy) as CEO, who stabilized the company and executed the Optum strategy that transformed UnitedHealth into the healthcare behemoth it is today.

The path from a small Minneapolis HMO to the world's largest healthcare company was marked by near-bankruptcy, public backlash against managed care, a $900 million loss, a CEO scandal, and constant political threats to the company's business model. UnitedHealth survived through relentless acquisition, operational discipline, and the strategic insight that healthcare's future lay not just in paying claims but in managing the entire healthcare value chain.

Creation of Optum — From Insurer to Health Services Platform

UnitedHealth Group formally organized its health services businesses under the Optum brand, signaling a strategic pivot from being primarily a health insurer to becoming a vertically integrated healthcare company that owns care delivery, pharmacy benefits, and technology alongside insurance.

Aggressive Physician Practice Acquisition

UHG accelerated its strategy of acquiring physician practices and employing doctors directly through Optum Health, growing from approximately 30,000 to 90,000+ physicians. The $4.9 billion DaVita Medical Group acquisition was the largest single deal in this push.

Pivot from HMO Restrictions to Value-Added Services

After a $900 million loss and public backlash against managed care restrictions, UHG pivoted from controlling costs through care denial to adding value through technology, data analytics, and care management programs that improved outcomes while reducing costs.

Medicare Advantage Expansion

UHG aggressively expanded into Medicare Advantage (privately administered Medicare plans) as the Medicare Modernization Act of 2003 increased government payments to private Medicare plans. UHG became the largest Medicare Advantage insurer in America.

UnitedHealth Group Incorporated: UnitedHealth Group Incorporated: Expert Analysis

UnitedHealth Group Incorporated: UnitedHealth Group Incorporated: Founders

How Does UnitedHealth Group Incorporated Make Money?

UnitedHealth Group's business model is best understood not as a health insurance company that has diversified into adjacent services, but as a vertically integrated healthcare platform that used insurance scale as the foundation for assembling an end-to-end healthcare value chain spanning coverage, pharmacy, care delivery, and data analytics. The architecture of that platform — how each component generates revenue, what the margin profile looks like across segments, and how the pieces interact to compound internal value — is central to both the company's extraordinary financial performance and its deepening regulatory vulnerability.

THE INSURANCE ENGINE: UNITEDHEALTHCARE

UnitedHealthcare, the insurance segment, generated approximately $281 billion in premium and administrative fee revenues for fiscal year 2024, making it the single largest source of consolidated top-line revenue and the anchor relationship through which all Optum services are ultimately delivered. The segment serves approximately 50 million members through four primary lines of business.

Commercial and Specialty Benefits serves approximately 27 million members through employer-sponsored group plans, small business products, and individual/family market coverage. This business operates in two economic modes. Fully insured plans, in which UnitedHealthcare assumes the actuarial risk of member medical costs, generate premium revenue from which the company must cover claims, administrative expenses, broker commissions, and state premium taxes before producing operating profit. Administrative Services Only arrangements, in which large employers self-fund the insurance risk and hire UnitedHealthcare as an administrator, generate fee revenues without premium underwriting risk. The ratio of fully insured to ASO membership has shifted toward ASO over time as larger employers prefer to retain risk on their balance sheets; this mix shift moderates premium revenue growth but also reduces earnings volatility, since ASO fee income is more predictable than underwriting income.

Medicare and Retirement serves approximately 8.7 million Medicare Advantage members, plus millions more enrolled in Medicare Supplement (Medigap) plans and Medicare Part D stand-alone prescription drug plans. Medicare Advantage operates on a capitated payment structure: the Centers for Medicare and Medicaid Services pays UnitedHealthcare a risk-adjusted monthly premium for each enrolled senior, calibrated to that member's demographic profile and health status coding under the Hierarchical Condition Categories (HCC) risk adjustment methodology. UnitedHealthcare then bears full financial responsibility for covered medical services for the contract year, with upside if aggregate medical costs are below the capitation rate and downside exposure if they exceed it. The economics depend critically on actuarial accuracy in risk adjustment, care management program effectiveness (which reduces avoidable hospitalizations and emergency utilization), and the adequacy of CMS benchmark rates relative to actual medical cost trends. This segment has historically been the company's highest-growth and highest-margin insurance product; 2024 saw significant margin pressure from higher-than-expected outpatient utilization, specialty pharmacy costs (particularly for GLP-1 medications), and CMS rate adjustments that tightened benchmark payments.

Community and State manages Medicaid and Children's Health Insurance Program benefits for state governments covering approximately 8 million low-income and disabled individuals across more than 30 states. Medicaid managed care operates on state-issued capitation contracts where per-member per-month rates are established through state procurement and negotiation with the state Medicaid agency. Margins are structurally lower than commercial or Medicare Advantage, reflecting the higher average medical acuity of low-income populations, behavioral health complexity, and the political constraints on state actuarial rate-setting. Medicaid redetermination following the end of the COVID-19 public health emergency — which had required continuous enrollment of all Medicaid recipients regardless of eligibility changes — drove significant membership volatility beginning in mid-2023, as states resumed eligibility reviews and disenrolled millions of individuals whose circumstances had changed.

Global provides insurance coverage in selected international markets including Brazil, Chile, Colombia, Portugal, and multinational employer expatriate programs. International revenues represent a modest fraction of consolidated results but provide geographic diversification and operational optionality in markets where managed care and insurance infrastructure are developing.

The insurance segment's margin profile is structurally narrow. After paying medical claims at a medical loss ratio of approximately 83 to 86 percent of premiums, covering administrative costs (broker commissions, premium taxes, operational infrastructure, regulatory compliance) of approximately 11 to 13 percent, and paying intercompany fees to Optum subsidiaries for pharmacy and services, the insurance segment generates operating margins in the 4 to 6 percent range. These margins are supplemented by investment income generated on the insurance float — premiums are collected in advance of claims payment, creating a pool of invested assets that earns returns in fixed-income and equity markets — which represents a meaningful earnings contribution that scales with premium volume.

THE SERVICES ENGINE: OPTUM

Optum generated approximately $236 billion in revenues in fiscal year 2024, including both external revenues from third-party clients and intercompany revenues from UnitedHealthcare. Optum is organized into three operating divisions with distinct revenue models, margin profiles, and competitive dynamics.

OptumRx is one of the three largest pharmacy benefit managers in the United States, managing pharmaceutical benefits for approximately 65 million members and processing approximately 1.4 billion adjusted prescription transactions annually. The PBM business model captures value through multiple mechanisms. Spread pricing represents the difference between the amount OptumRx charges plan sponsor clients for dispensed prescriptions and the amount it reimburses retail pharmacy networks — a margin embedded in each transaction that has attracted regulatory scrutiny for its opacity. Manufacturer rebates, negotiated based on formulary placement commitments and volume guarantees with pharmaceutical companies, create a second revenue stream that has become the dominant political target of PBM critics, who argue that rebates incentivize formulary placement of higher-cost branded drugs over lower-cost alternatives. Administrative and clinical management fees from health plan and employer clients provide a third, more transparent revenue component. Specialty pharmacy management — encompassing the dispensing, patient support services, and clinical management of high-cost injectable, biologic, and rare disease medications — is the fastest-growing revenue segment within OptumRx, driven by the rapid adoption of GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) for diabetes and obesity management, biologic therapies for inflammatory diseases, and oncology medications. Specialty drugs represent a small share of total prescription volume but a large and rapidly growing share of total pharmaceutical expenditure.

Optum Health represents the company's direct patient care delivery capabilities, employing more than 60,000 physicians, nurse practitioners, physician assistants, and other advanced practice clinicians across more than 2,000 care delivery sites in the United States. This care delivery network was assembled over a decade of physician group acquisitions across the country, anchored by the $4.9 billion purchase of DaVita Medical Group in 2017, which added approximately 300 medical clinics and 35 urgent care centers across six states. Optum Health generates revenue through fee-for-service professional services at owned and affiliated clinic sites; capitated arrangements in which Optum bears clinical and financial risk for attributed patient populations under Medicare Advantage and commercial value-based contracts; shared savings and shared risk arrangements under CMS Innovation Center programs and commercial accountable care organization structures; home health and visiting nurse services; and ambulatory surgical care at owned surgical centers. The most strategically and financially leveraged component is value-based primary care for Medicare Advantage members: when Optum Health clinicians serve as the primary care medical home for UnitedHealthcare Medicare Advantage enrollees under risk-bearing contracts, both the clinical quality (which affects CMS Star Ratings and member satisfaction) and medical cost performance flow directly to UnitedHealthcare's financial results, creating operating leverage across both segments simultaneously. The care delivery model also generates the longitudinal clinical data that feeds Optum Insight analytics, creating internal network effects across the three Optum businesses.

Optum Insight provides health information technology, data analytics, research services, revenue cycle management solutions, and clinical decision support tools to hospitals, health systems, physician practices, health plans, life sciences companies, and federal and state government clients. The business generates revenue from software subscription licenses, transaction processing fees for claims and eligibility verification, long-term administrative services outsourcing contracts, and professional advisory services. Optum Insight's strategic importance to the enterprise exceeds its direct revenue contribution because it provides the data infrastructure that makes vertical integration economically viable: by processing claims, prior authorization requests, eligibility verifications, and payment transactions for thousands of healthcare organizations beyond UnitedHealth Group's own insurance business, Optum Insight generates a de-identified longitudinal dataset of healthcare interactions that informs actuarial models, population health programs, and fraud detection capabilities across the enterprise. The February 2024 ransomware attack on Change Healthcare — acquired as part of Optum Insight for $13 billion in 2022 after defeating a DOJ antitrust challenge — disrupted these functions at scale, creating direct costs exceeding $3.1 billion and triggering ongoing regulatory investigations and client relationship damage.

THE INTEGRATION FLYWHEEL AND ITS ECONOMICS

The most important feature of UnitedHealth Group's business model is not any individual segment but the economic interactions between them. When UnitedHealthcare insures an employer's workforce, OptumRx can manage their pharmacy benefits, Optum Health can provide primary care through owned clinics, and Optum Insight can handle claims processing infrastructure — with each service generating margin that would otherwise accrue to external vendors and each service improving the financial performance of the insurance segment by reducing medical costs or improving administrative efficiency. The more of these services are captured internally, the higher the consolidated operating margin per premium dollar, and the more competitive the company can be on insurance pricing relative to competitors who must outsource these functions. This flywheel is the source of both the company's extraordinary revenue growth — from under $100 billion in 2010 to over $400 billion in 2024 — and its fundamental regulatory challenge.

Revenue Streams

• UnitedHealthcare (Insurance) (~56%): Health insurance premiums from employer-sponsored plans, Medicare Advantage, Medicaid, and individual market coverage serving 50+ million members. Includes UnitedHealthcare Employer & Individual and UnitedHealthcare Medicare & Retirement.
• Optum Health (Care Delivery) (~22%): Direct healthcare delivery through 90,000+ employed or affiliated physicians, ambulatory surgery centers, urgent care clinics, and home health services. Serves approximately 103 million patients.
• Optum Rx (Pharmacy Benefits) (~15%): Pharmacy benefit management (PBM) services including prescription drug pricing negotiation, mail-order pharmacy, specialty pharmacy, and formulary management for health plans and employers.
• Optum Insight (Technology & Analytics) (~7%): Healthcare technology services including claims processing, revenue cycle management, data analytics, consulting, and AI-powered clinical decision support for hospitals and health systems.

What Products and Services Does UnitedHealth Group Incorporated Offer?

What Is UnitedHealth Group Incorporated's Competitive Advantage?

UnitedHealth Group's competitive advantages are structural rather than merely operational — embedded in the architecture of the enterprise rather than dependent on any single product, technology cycle, or individual leader. Understanding them requires examining the company not as an insurer with services attached, but as a vertically integrated platform whose individual components create value for each other in ways that pure-play competitors, by definition, cannot replicate.

The most durable source of competitive advantage is scale in data and transaction processing. UnitedHealth Group processes more healthcare transactions annually than any other private entity in the United States. Through UnitedHealthcare's insurance operations, it administers claims for approximately 50 million members. Through OptumRx, it manages pharmacy benefits for more than 65 million people. Through Optum Insight and the acquired Change Healthcare network, it processes claims, prior authorization requests, and payment transactions for thousands of hospitals and physician groups that have no insurance relationship with UnitedHealth Group at all. This creates a data asset — billions of de-identified, longitudinal healthcare transactions — that enables actuarial precision, fraud detection capability, population health analytics, and formulary optimization that smaller competitors simply cannot replicate at comparable fidelity. The data advantage compounds over time: larger datasets generate more accurate predictive models, which generate better risk selection, more effective care management, and more precise actuarial pricing, which improves financial performance, which funds further data acquisition and analytical investment.

The economic complementarity between UnitedHealthcare's insurance relationships and Optum's services businesses creates a second category of structural advantage. When UnitedHealthcare health plan members use OptumRx for pharmacy benefits, they generate operating margin for Optum that would otherwise flow to a third-party PBM. When members receive primary care at Optum Health clinics under value-based arrangements, care coordination reduces downstream medical costs — hospitalizations, emergency visits, specialist referrals — that would otherwise increase UnitedHealthcare's medical loss ratio. When Optum Insight provides claims processing infrastructure to hospitals and physician groups that also bill UnitedHealthcare, the data integrations create relationships and operational dependencies that generate switching costs for both the providers and the insurer. Each Optum service makes the insurance segment more valuable; the insurance segment provides a guaranteed customer base that makes the Optum services economically viable at lower customer acquisition costs than standalone competitors face.

Medicare Advantage market leadership represents a third structural advantage that benefits from significant scale economics. As the nation's largest Medicare Advantage operator with more than 8.7 million enrollees, UnitedHealthcare achieves actuarial scale in risk adjustment modeling, administrative efficiency across its fixed cost base, and network bargaining leverage with hospital systems and specialty groups that regional competitors cannot match. The MA market rewards scale through better HCC coding precision, richer supplemental benefits enabled by administrative efficiency, and the ability to invest in care management programs — 24/7 nurse lines, chronic disease coaching, hospital at home services — that improve clinical outcomes and reduce medical costs. The cumulative effect is a competitive product that can offer richer benefits at lower member premiums than smaller, local MA plans, reinforcing market leadership through a feedback loop that has operated for more than a decade.

OptumRx's position as one of the three dominant pharmacy benefit managers confers manufacturer negotiating leverage that is a direct function of enrollment scale. Formulary control over tens of millions of covered lives gives OptumRx the ability to demand — and receive — drug rebates, discounts, and pricing terms from pharmaceutical manufacturers that smaller PBMs cannot access. While the PBM rebate model faces sustained political pressure, the fundamental negotiating dynamics of pharmaceutical economics continue to reward the largest operators with disproportionate commercial terms.

Finally, the capital generation capability of the consolidated enterprise — historically producing more than $20 billion in annual operating cash flow — enables sustained investment in physician group acquisitions, technology platforms, and data assets that compound all of the above advantages. The financial capacity to acquire strategically important assets at prices that create short-term earnings dilution but long-term platform enhancement, and to sustain operations through major disruptions as demonstrated in the Change Healthcare attack, is itself a competitive advantage that smaller, less diversified competitors cannot replicate.

Who Are UnitedHealth Group Incorporated's Main Competitors?

The competitive landscape in which UnitedHealth Group operates is unusual in American industry: a sector of enormous aggregate scale that is simultaneously highly concentrated at the national level and intensely competitive at the local product level, with different competitive dynamics governing each segment of the company's diversified business.

In commercial employer-sponsored insurance, UnitedHealth Group's primary competitors are Elevance Health (formerly Anthem), Cigna Group, and Aetna (now operated as a subsidiary of CVS Health). These four companies collectively control a dominant share of the commercially insured employer market. Elevance Health, with approximately 47 million total medical members enrolled across its affiliated Blue Cross Blue Shield plans in 14 states and additional non-Blue markets, competes directly with UnitedHealthcare in large employer accounts through the brand recognition and local market depth of the BCBS network. Elevance's recently deepened services strategy — including the Carelon health services subsidiary that mirrors Optum's structure — reflects the industry's recognition that pure insurance is insufficient as a long-term competitive model. Cigna Group, operating its commercial insurance products alongside the Express Scripts pharmacy benefit management business (now organized under the Evernorth health services subsidiary), has pursued a strategy structurally analogous to UnitedHealth Group's integration thesis: combining insurance underwriting with one of the three dominant PBMs to capture pharmacy economics that would otherwise leave the enterprise. CVS Health/Aetna represents perhaps the most architecturally similar competitive challenge, with CVS having assembled — through the $69 billion Aetna acquisition in 2018, the $8 billion Signify Health acquisition in 2023, and the $10.6 billion Oak Street Health acquisition — a combination of insurance underwriting, pharmacy retail, pharmacy benefit management through CVS Caremark, and primary care delivery that mirrors UnitedHealth Group's integrated model closely enough that regulators and analysts frequently treat them as competing implementations of the same vertical integration thesis.

In Medicare Advantage, UnitedHealthcare's most direct and consequential competitor is Humana. Humana has for years ranked as the second-largest Medicare Advantage operator in the United States, with approximately 5.6 million MA enrollees, and its strategic concentration in the senior market — expressed through CenterWell primary care clinic investments and home health acquisitions — makes it the most focused competitive threat in what is arguably UnitedHealthcare's highest-priority business segment. Humana's concentrated exposure to Medicare Advantage, which accounts for approximately 80% of its revenue, has created vulnerability during periods of adverse MA economics — notably 2023 and 2024, when medical cost trends exceeded industry-wide expectations — but the same concentration has generated deep operational expertise in senior care management, risk adjustment, and population health that UnitedHealthcare must match to maintain leadership. Humana's willingness to operate at lower commercial scale in exchange for MA depth represents a deliberate strategic choice that has produced a genuinely capable rival in the senior health market.

Centene Corporation represents the primary competitor to UnitedHealthcare Community and State in managed Medicaid. With more than 28 million Medicaid and CHIP members and state contracts in most major Medicaid markets, Centene's scale in government-sponsored insurance for low-income populations rivals UnitedHealthcare's across the largest state programs. Centene's organizational identity is fundamentally shaped by Medicaid: the company has developed deep capabilities in navigating state procurement processes, managing behavioral health comorbidities in low-income populations, maintaining community relationships that influence state contract renewals, and operating on the thin margins that Medicaid actuarial rates permit. These capabilities represent a genuine competitive differentiation in markets where UnitedHealthcare competes but does not hold a structural leadership position.

In pharmacy benefit management, OptumRx competes with Express Scripts (owned by Cigna/Evernorth) and CVS Caremark in a three-firm oligopoly that collectively manages pharmaceutical benefits for the majority of Americans with prescription drug coverage. The PBM market is undergoing significant competitive and regulatory stress as state legislators, federal regulators, and employer clients push for greater transparency in rebate arrangements, spread pricing practices, and formulary construction. The Federal Trade Commission's multi-year investigation into PBM business practices produced a preliminary report in mid-2024 that characterized the three large PBMs as engaged in practices that raise drug costs for consumers and disadvantage independent pharmacies — creating legislative momentum for transparency and reform requirements that could structurally alter the economics of all three businesses. Each of the dominant PBMs faces similar pressure, but the degree to which that pressure translates into revenue compression depends on business model adaptation speed and the specific legislative outcomes at federal and state levels.

The competitive landscape is increasingly being reshaped by technology companies and consumer-oriented platforms whose healthcare entries — modest in scale today — represent the most credible long-term structural challenge to UnitedHealth Group's position in health services. Amazon's strategy is the most ambitious among these newer entrants. Through One Medical primary care (acquired for $3.9 billion in 2023), Amazon Pharmacy retail dispensing, Amazon Clinic telehealth, and Amazon Health Services employer program management, Amazon is assembling a consumer-facing primary care and pharmacy platform that draws on its existing relationships with more than 170 million US Prime members and its proven competencies in logistics, consumer experience design, and platform marketplace economics. Amazon's healthcare revenue remains negligible relative to UnitedHealth Group's, but the strategic rationale is clear: establish patient relationships through consumer-friendly digital entry points, then expand into the higher-margin care delivery and pharmacy services where Optum Health and OptumRx currently operate with relatively limited consumer visibility.

Apple's growing health data capabilities — including HealthKit's longitudinal health data collection, Apple Watch's FDA-cleared ECG and blood oxygen monitoring, and rumored continuous glucose monitoring development — position the company as a potential long-term disruptor of health data economics. If Apple successfully aggregates personal health data at scale and makes it available to competing health plans or care delivery organizations, it could erode a portion of the data advantage that currently differentiates Optum's analytics business. Microsoft, through its Azure cloud partnerships with Epic Systems and major health systems, its investment in clinical AI models, and its partnership with Nuance (the ambient AI clinical documentation company), is positioning as a health information technology infrastructure provider that could either complement or eventually compete with Optum Insight's data and technology services franchise.

The aggregate competitive picture for UnitedHealth Group is one of extraordinary current market position combined with genuine medium-term structural vulnerability. No single competitor challenges the company comprehensively across insurance, pharmacy, care delivery, and health IT simultaneously — but the cumulative pressure from specialized, focused rivals in each segment means the company must execute competitively across multiple distinct competitive markets simultaneously, with no product line where benign neglect is strategically affordable.

How Has UnitedHealth Group Incorporated's Revenue Grown Over Time?

UnitedHealth Group's financial profile is defined by an unusual combination: enormous revenue scale generated by insurance premium flows, paired with structurally narrow insurance margins that are substantially enriched by Optum's higher-margin health services businesses. Understanding the consolidated financial picture requires examining segment-level economics rather than treating the aggregate income statement as a monolithic unit.

For fiscal year 2024, UnitedHealth Group reported total revenues of $400.3 billion, a 7.8% increase over fiscal year 2023's $371.6 billion and a continuation of the company's decade-long pattern of compounding revenue growth. The UnitedHealthcare segment contributed approximately $281 billion in premium and fee revenues, while Optum generated approximately $236 billion in revenues including significant intercompany transactions with UnitedHealthcare. Intercompany eliminations, which remove revenues recorded by both segments for services exchanged within the enterprise, reduce the consolidated total to $400.3 billion and represent a concrete financial expression of the vertical integration strategy.

Total operating income before Change Healthcare-related costs was approximately $18.9 billion for fiscal year 2024. However, the $3.1 billion in direct Change Healthcare cyberattack costs — remediation expenses, provider advance payments, temporary infrastructure, and settlement-related reserves — reduced reported operating income substantially. Adjusted net earnings attributable to UnitedHealth Group common shareholders were approximately $14.4 billion. The company's effective tax rate of approximately 21% reflected a combination of statutory federal rates and state tax obligations across its diversified geographic operations.

The medical loss ratio for the UnitedHealthcare segment rose above historical levels during 2024, reaching approximately 85.2% for the full year compared to approximately 82.8% in 2022. The MLR elevation reflected higher-than-anticipated Medicare Advantage medical costs — particularly for outpatient services, GLP-1 pharmaceutical spending, and post-acute care utilization — that the company's actuarial models had not fully anticipated. This MLR pressure was the primary driver of the earnings revisions and stock price decline that occurred through 2024.

Optum's margin profile meaningfully exceeded the insurance segment. OptumRx, as a PBM and specialty pharmacy operator, generated operating margins in the mid-to-high single digits on its enormous transaction volumes. Optum Health's care delivery business, operating increasingly on value-based risk contracts, generated higher margins on attributed Medicare populations where care management effectiveness drove medical cost savings. Optum Insight's software and data analytics products generated the highest operating margins within the enterprise, in line with health IT software industry benchmarks, though these were partially offset by remediation costs following the Change Healthcare attack.

Free cash flow generation, historically one of the company's strongest financial metrics, produced approximately $21-22 billion in cash from operations in fiscal year 2024. The insurance business model's working capital dynamics — premiums collected in advance of claims payment — support cash conversion ratios that often exceed reported net income, providing substantial capital for dividend payments, share repurchases, debt service, and selective acquisitions. The company has been a consistent dividend grower, maintaining its pattern of annual dividend increases that reflects management's confidence in the long-term earnings trajectory even during periods of operational disruption. Long-term debt of approximately $47 billion as of year-end 2024 reflects the cumulative capital deployed in major acquisitions over the preceding decade.

Revenue History Source: SEC filing

What Companies Has UnitedHealth Group Incorporated Acquired?

UnitedHealth Group Incorporated: UnitedHealth Group Incorporated: Controversies & Legal Issues

Who Leads UnitedHealth Group Incorporated?

How Is UnitedHealth Group Incorporated Growing?

UnitedHealth Group's near-term and medium-term growth strategy under Stephen Hemsley's renewed leadership is organized around five priorities: stabilizing Medicare Advantage economics, expanding Optum Health's value-based care capabilities, defending and incrementally growing OptumRx's specialty pharmacy position, rebuilding Optum Insight's market credibility following the Change Healthcare attack, and managing the regulatory environment with enough credibility to preclude forced structural changes.

Medicare Advantage margin restoration is the most pressing financial priority. The company has signaled a managed enrollment strategy that prioritizes profitability over volume for the first time in a decade — deliberately exiting or repricing plans in geographic markets where medical cost trends have been most adverse, reducing supplemental benefit offerings that attracted members but contributed disproportionately to MLR elevation, and investing in enhanced HCC risk adjustment precision to better capture the clinical complexity of enrolled populations in capitation rate negotiations with CMS. The near-term consequence is slower enrollment growth and potential absolute membership declines in certain markets, but the strategic objective is restoration of sustainable operating margins in the 4 to 5 percent range on Medicare Advantage premiums before resuming growth investment.

Optum Health's growth strategy centers on the continued expansion of value-based primary care — an operating model in which Optum Health clinicians bear clinical and financial risk for attributed patient populations under capitated or shared-savings contracts, rather than generating fee-for-service revenue that lacks economic alignment with health outcomes. The value-based model, when executed well, creates alignment between clinical incentives and economic results: physicians in risk-bearing arrangements who reduce preventable hospitalizations, manage chronic disease populations effectively, and coordinate post-acute care efficiently generate operating margin for the enterprise while improving patient outcomes and CMS Star Ratings. Optum Health's acquisition strategy has shifted from geographic coverage building to quality deepening — prioritizing the integration of existing physician networks into more sophisticated risk-bearing arrangements rather than adding new clinic locations.

OptumRx's specialty pharmacy strategy involves deepening clinical management capabilities for the most complex and expensive drug categories. For GLP-1 medications, this means developing adherence monitoring programs, prior authorization protocols, and outcomes measurement frameworks that health plan clients and employers value as managing not just drug costs but patient health trajectories. For cell and gene therapies — one-time treatments with costs in the hundreds of thousands to millions of dollars — OptumRx is developing outcomes-based contracting models with manufacturers that link payment to treatment efficacy, a capability that requires clinical sophistication and manufacturer relationship depth unavailable to smaller PBM competitors.

Optum Insight's recovery strategy involves demonstrating the security improvements, business continuity investments, and operational resilience that healthcare system clients now require as conditions of long-term technology infrastructure partnerships. The company has committed to substantial cybersecurity infrastructure investment, independent security certification processes, and redundancy architecture for claims processing that eliminates single points of failure. The long-term market thesis — that hospital systems and physician practices will continue outsourcing administrative complexity to specialized technology service providers — remains structurally intact; the Change Healthcare attack represented a security execution failure rather than an invalidation of the business model.

Capital allocation under Hemsley will reflect a conservative posture: modest dividend growth, disciplined share repurchases that reflect confidence in long-term value without being programmatic, targeted debt reduction to strengthen the balance sheet against regulatory and litigation uncertainty, and highly selective acquisition activity focused on small, capability-building additions rather than transformative deals that would attract antitrust scrutiny the company can ill afford in the current regulatory environment.

UnitedHealth Group's future competitive and financial trajectory is best understood through two competing scenarios: a base case in which its vertical integration proves durable and regulatory challenges are absorbed without structural dismemberment, and a bear case in which compounding pressure from antitrust enforcement, prior authorization regulation, Medicare Advantage rate compression, and competitive disruption from technology-native entrants impairs the profit architecture that has driven the company's extraordinary performance.

The bull case rests on the continued expansion of Optum as a services revenue generator capable of offsetting near-term margin pressure in the insurance segment. OptumRx has a substantial opportunity to expand its role in specialty pharmacy management as GLP-1 medications — semaglutide-class drugs for obesity and diabetes that are becoming among the most prescribed medications in American history — and cell and gene therapies represent rapidly growing shares of total pharmaceutical spending. Managing these categories effectively requires exactly the clinical management, step therapy, manufacturer negotiation, and patient support capabilities that a large, integrated PBM is best positioned to deliver. Optum Health's value-based primary care network positions the company to benefit from the structural migration of care from inpatient hospitals to ambulatory settings — a shift driven by CMS payment incentives, private equity investment in outpatient infrastructure, and consumer preference for convenient care access — which improves both clinical economics and operating margins in capitated arrangements. Medicare Advantage enrollment, despite near-term profitability pressure, remains one of the most structurally attractive markets in American healthcare, with demographic projections supporting continued MA enrollment growth as Baby Boomers age through Medicare eligibility and the MA penetration rate — now above 53% of Medicare eligibles — continues to expand.

The bear case centers on the cumulative impact of regulatory and competitive disruption. A Department of Justice antitrust enforcement outcome requiring the divestiture of Change Healthcare, OptumRx, or Optum Health would not merely reduce revenue — it would dissolve the intercompany economics that account for a disproportionate share of consolidated profitability and undermine the fundamental logic of the vertical integration strategy. Federal prior authorization reform legislation that meaningfully reduces denial rates would increase medical costs without offsetting revenue increases, structurally widening the medical loss ratio. Sustained CMS rate compression in Medicare Advantage, if regulators determine that the program's growth has outpaced its managed care efficiency benefits, could erode the economics of the company's highest-profile growth product faster than the care management infrastructure can compensate.

The Amazon competitive scenario remains uncertain but directionally important. If Amazon successfully builds an employer health program combining One Medical primary care access with Amazon Pharmacy convenience and Amazon Clinic telehealth at scale — and if it can offer this to large employers as a differentiated alternative to traditional insurance-plus-services packages — it begins competing for the commercial employer relationships that form UnitedHealthcare's core franchise. Amazon's competitive patience and capital depth make this a scenario that cannot be dismissed on current scale alone.

Management under Stephen Hemsley will likely pursue a strategy of operational execution, regulatory credibility restoration, and selective capital return over aggressive acquisition — a recognition that the company's challenges require demonstrating existing platform quality rather than adding complexity.

What Are the Biggest Risks Facing UnitedHealth Group Incorporated?

UnitedHealth Group entered the second half of the 2020s carrying a heavier burden of simultaneous challenges than at any point in its modern history, with legal, regulatory, reputational, and operational risks converging in a way that tests the resilience of the underlying business model rather than merely requiring tactical responses.

The most immediately quantifiable challenge is the ongoing financial and operational fallout from the February 2024 Change Healthcare ransomware attack. When ALPHV/BlackCat encrypted Change Healthcare's systems, the attack did not merely cost UnitedHealth money — it revealed to regulators, lawmakers, and the public just how much of the American healthcare payment infrastructure depended on a single, recently acquired subsidiary. The Department of Health and Human Services launched investigations into the data security practices that permitted the breach. Congress held hearings at which UnitedHealth executives faced pointed questions about the concentration of critical healthcare infrastructure in a single private company. The American Medical Association and hospital industry groups documented the disruption to thousands of practices and facilities that lost claims submission capability for weeks. By the time direct costs were tallied — including system remediation, advance payments to providers to sustain cash flow, temporary operational infrastructure, and disruption payments — the bill exceeded $3.1 billion, with additional litigation and regulatory costs continuing to accumulate. The attack also raised the company's cybersecurity investment obligations permanently, as regulators and clients now demand higher standards of resilience and redundancy from healthcare data infrastructure than existed before the incident.

The antitrust environment represents a structural threat that predates the ransomware attack but intensified considerably in its aftermath. The Department of Justice had already challenged the Change Healthcare acquisition in 2022, arguing that combining Optum Insight with the largest healthcare claims clearinghouse in the country would give the combined entity anticompetitive control over the data flows underlying the entire healthcare payment system. A federal district court rejected that argument and the deal closed — but the DOJ's concerns about UnitedHealth Group's vertical integration did not dissipate. By 2024 and 2025, DOJ antitrust scrutiny broadened to examine the company's combined position across insurance, pharmacy benefit management, and care delivery more holistically, raising the possibility that the company could face forced divestiture of assets that underpin its current revenue and profit model. An antitrust enforcement outcome requiring the separation of OptumRx or Optum Insight from the insurance business would not merely reduce revenue — it would disrupt the internal economics that justify the company's current operating margin profile.

Congressional pressure on prior authorization practices adds a legislative dimension to the company's regulatory exposure. Multiple bills introduced in both chambers would require health insurers — UnitedHealthcare being the most frequently cited target in congressional testimony — to reduce prior authorization burdens, accelerate approval timelines, limit the use of algorithmic or AI-based denial systems without physician oversight, and improve transparency around denial rates and appeal outcomes. While comprehensive prior authorization reform has repeatedly failed to advance through a fractured legislative process, the political momentum has never been stronger, partly as a direct consequence of public discourse following the Brian Thompson killing in December 2024 and the torrent of testimony about claim denial experiences that followed.

The reputational dimension of the Thompson killing cannot be dismissed as temporary or fully containable. Public polling conducted in the months after the event consistently showed that a majority of Americans held negative views of health insurance companies and specifically associated UnitedHealthcare with excessive claim denials. For a company whose commercial insurance products compete partly on employer perception, broker advocacy, and consumer satisfaction scores — all of which inform plan selection during annual open enrollment cycles — sustained negative brand association creates competitive risk that is difficult to quantify but real. The asymmetry of the cultural moment was notable: the volume and intensity of anti-insurer commentary online significantly exceeded what any prior news event related to the company had generated, suggesting the incident activated pre-existing sentiment that will not quickly dissipate.

On the medical economics front, UnitedHealthcare faces the challenge of restoring Medicare Advantage margins to levels that justify continued investment in the product. Rising utilization of outpatient services, the explosive growth in spending on GLP-1 medications that CMS capitation rates did not fully anticipate, and higher-than-expected inpatient readmission rates in certain Medicare Advantage markets pressured the segment's MLR above historic levels across multiple quarters in 2024. Slowing enrollment growth — as the company deliberately repriced or exited unprofitable markets — reduces the scale advantage that historically helped absorb medical cost volatility. The competitive dynamics of Medicare Advantage, including intensifying broker competition and CMS rate pressure, mean that the company cannot simply raise premiums to recover margins without accepting member attrition to lower-priced rivals.

The competitive threat from Amazon, while still speculative in scale, introduces a category of risk that traditional managed care companies are institutionally ill-positioned to confront. Amazon's One Medical acquisition, Amazon Pharmacy expansion, and Amazon Clinic telehealth launch signal a patient-centric care delivery strategy that competes directly with Optum Health in markets where consumer experience and digital convenience can displace incumbent relationships. Amazon's ability to cross-subsidize healthcare services against its core retail and cloud businesses gives it a competitive patience that insurance-industry economics cannot easily match.

UnitedHealth Group Incorporated: UnitedHealth Group Incorporated: Quick Reference Q&A

UnitedHealth Group Incorporated: UnitedHealth Group Incorporated: Frequently Asked Questions: UnitedHealth Group Incorporated

UnitedHealth Group Incorporated: UnitedHealth Group Incorporated: Sources & References

• UnitedHealth Group 2024 Annual Report (Form 10-K) [annual_report]
• UnitedHealth Group Q4 and Full Year 2024 Earnings Release [earnings_release]
• DOJ Complaint: United States v. UnitedHealth Group Inc. And Change Healthcare Inc. [regulatory_filing]
• HHS Office for Civil Rights — Change Healthcare Cybersecurity Incident [government_report]
• SEC EDGAR Company Facts — UnitedHealth Group Incorporated [sec_filing]